Bessemer Group
CBMG

Bessemer Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bessemer Group’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-48,900
Closed -$732K – 1782
2020
Q2 		$732K Buy
+48,900
New +$698K ﹤0.01% 886

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bessemer Group's CBMG Position: Q3 2020 in Review

Bessemer Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2020, closing a stake of 48,900 shares — an estimated $732K sold.

Bessemer Group first reported a position in CBMG in Q2 2020 and held it in 1 quarter. The position peaked at $732K in Q2 2020. 73 funds tracked by Wall St. Rank hold CBMG as of Q3 2020.

  • Bessemer Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 48,900 Cellular Biomedicine Group, Inc. shares in Q3 2020, an estimated $732K.
  • Bessemer Group first reported a position in Cellular Biomedicine Group, Inc. in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's Cellular Biomedicine Group, Inc. position peaked at $732K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.